Neimeth International Pharmaceuticals reported a 62 percent jump in third-quarter sales, reaching N5.01 billion for the period ending September 30, 2025, compared with N3.09 billion a year earlier. Gross profit climbed 71 percent to N2.49 billion, while operating income rose 120 percent to N1.66 billion, reflecting gains from expanded business activities.
The company kept marketing and distribution costs in check, with expenses up just 6 percent to N437.4 million, though administrative outlays swelled 67 percent amid inflationary and foreign exchange pressures. A sharp 198 percent surge in finance charges to N1.3 billion curtailed earnings growth, resulting in net profit of N339.8 million, a modest 9 percent increase over the prior period.
Neimeth’s balance sheet showed total assets of N13.35 billion, up from N11.99 billion at December 2024, and liabilities rising to N11.35 billion from N10.34 billion. Net asset value improved 21 percent to N1.99 billion. Operating cash flow generated N1.5 billion, largely offset by a N1.42 billion financing outlay. Earnings per share stood at 7.95 kobo, compared with 7.27 kobo in the same nine-month period of 2024.
The company kept marketing and distribution costs in check, with expenses up just 6 percent to N437.4 million, though administrative outlays swelled 67 percent amid inflationary and foreign exchange pressures. A sharp 198 percent surge in finance charges to N1.3 billion curtailed earnings growth, resulting in net profit of N339.8 million, a modest 9 percent increase over the prior period.
Neimeth’s balance sheet showed total assets of N13.35 billion, up from N11.99 billion at December 2024, and liabilities rising to N11.35 billion from N10.34 billion. Net asset value improved 21 percent to N1.99 billion. Operating cash flow generated N1.5 billion, largely offset by a N1.42 billion financing outlay. Earnings per share stood at 7.95 kobo, compared with 7.27 kobo in the same nine-month period of 2024.
